A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

November 25, 2025

Study Completion Date

April 27, 2026

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK3862995B

GSK3862995B will be administered.

DRUG

Placebo

Matching placebo will be administered.